Nandrolone for Anemia in Adult Males
Nandrolone decanoate is FDA-approved specifically for anemia of renal insufficiency in adult males at a dose of 100-200 mg intramuscularly per week, but current evidence does not support its routine use given the availability of safer, more effective alternatives like erythropoietin-stimulating agents (ESAs). 1
FDA-Approved Indication and Dosing
Nandrolone decanoate is indicated exclusively for management of anemia of renal insufficiency 1. The FDA-approved dosing regimen is:
- Adult males: 100-200 mg intramuscularly per week
- Women: 50-100 mg per week
- Children (2-13 years): 25-50 mg every 3-4 weeks
- Route: Deep intramuscular injection into gluteal muscle
- Duration: Discontinue if no hematologic improvement within 6 months 1
Critical Requirement
Adequate iron intake is mandatory for maximal response—nandrolone cannot overcome iron deficiency 1.
Clinical Context and Evidence Quality
While nandrolone can increase hemoglobin and hematocrit in renal anemia patients 2, 3, 4, the evidence base is limited to small studies from the 1990s-2000s, predating modern anemia management guidelines. A 2014 Cochrane review found insufficient evidence to confirm that androgens are beneficial for CKD-related anemia 5.
Comparative Effectiveness
Research comparing nandrolone to erythropoietin shows:
- Similar hemoglobin increases (both achieve ~3 g/dL rise over 6 months) 4, 6
- Lower cost than ESAs 4, 7
- Anabolic benefits: Increased serum albumin, total protein, transferrin, and body weight 3, 4
- Better blood pressure control: Fewer hypertensive complications than ESA therapy (6% vs 45%) 4
However, adding nandrolone to low-dose ESA does not provide significant additional benefit 2.
Contraindications (Absolute)
- Prostate cancer or suspicion thereof
- Breast cancer in males
- Hepatic dysfunction
- Hypercalcemia
- Pregnancy (Category X)
- Women of childbearing potential (due to virilization risk)
Adverse Effects and Monitoring
Common Side Effects
Endocrine/metabolic (most frequent):
- Virilization in women (voice deepening, hirsutism)—occurred in 4/16 female patients in one study, requiring discontinuation 2
- Lipid abnormalities: Increased triglycerides and LDL, decreased HDL 3, 8, 9
- Hepatotoxicity: Elevated ALT/AST 9
- Polycythemia (modest hematocrit increase) 10
Cardiovascular: Hypertension, thromboembolism risk 9
Psychiatric: Aggression, mood disorders, sleep disturbances 9
Required Monitoring
- Baseline: Complete blood count, comprehensive metabolic panel, lipid panel, liver function tests, PSA (males >40 years), digital rectal exam
- During therapy:
- Hemoglobin/hematocrit monthly initially, then every 3 months
- Liver function tests every 3 months
- Lipid panel every 3-6 months
- PSA every 6-12 months in males
- Discontinue if: No response in 6 months, PSA elevation >1.4 ng/mL over 1 year, hepatotoxicity, or intolerable virilization 11, 1
Clinical Algorithm for Use
Step 1: Confirm anemia of renal insufficiency
- Rule out iron, folate, B12 deficiency
- Assess for occult blood loss
- Verify adequate iron stores (ferritin >100 ng/mL, TSAT >20%)
Step 2: Consider patient-specific factors
- Preferred candidates: Males >55 years with CKD (best response rate) 7
- Avoid in: Women (virilization risk), patients with cardiovascular disease, hepatic dysfunction, or prostate concerns
Step 3: First-line therapy selection
- ESAs remain first-line for most patients with renal anemia 12
- Consider nandrolone only if: Cost is prohibitive, ESAs contraindicated, or patient is elderly male with good performance status
Step 4: If using nandrolone
- Start 100-200 mg IM weekly
- Ensure adequate iron supplementation
- Monitor response at 3 months; discontinue if hemoglobin increase <1 g/dL
Important Caveats
Not for non-renal anemia: No evidence supports use in cancer-related anemia, myelodysplastic syndrome, or other causes 13, 14
Not for COPD/muscle wasting: Despite theoretical benefits, guidelines explicitly recommend against routine use of anabolic agents in COPD rehabilitation (Grade 2C) 10
Gender considerations: The virilization risk makes nandrolone essentially contraindicated in premenopausal women 2, 7
Age-dependent response: Patients >55 years show significantly better hemoglobin responses (27 g/L increase) compared to younger patients (8 g/L increase) 7
Reversible effects: Lipid abnormalities normalize 4 months after discontinuation 8
Contemporary Practice Reality
In modern clinical practice, nandrolone has been largely supplanted by ESAs for renal anemia management. The primary remaining role is as a cost-saving alternative in resource-limited settings for carefully selected elderly males without contraindications, with close monitoring for adverse effects. The narrow therapeutic window, significant side effect profile, and availability of safer alternatives limit its utility in contemporary medicine.